In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the UK. Vaccination was offered to 45 individuals with an initial assessment of high exposure risk.
Introduction
The 2013-2016 Ebola virus (EBOV) outbreak in West Africa resulted in 28,646 reported cases of Ebola virus disease (EVD) and 11,323 deaths [1] . Healthcare workers were at particularly high-risk of infection with at least 500 deaths among 900 cases and amplified transmission of the disease in some healthcare settings. On the 29th December 2014, a nurse who had worked in a treatment centre in Sierra Leone was diagnosed with EVD on return to the UK [2] . Full protocols for the management of viral haemorrhagic fever (VHF) were instituted immediately. Of 3 individuals providing direct healthcare to the patient prior to transfer to the UK high level isolation unit, none were categorised as high-risk due to appropriate use of personal protective equipment (PPE). In contrast, when the same patient became unwell with a previously unreported complication of EVD reactivation associated with meningo-encephalitis between the 5 th -9 th October 2015 (the only reported late reactivation resulting in detectable viremia of 28,646 cases), 45 healthcare workers and household contacts were initially categorised as high-risk. An incident management team (IMT) was set up in order to consider post-exposure prophylaxis (PEP).
In October 2015, no licensed EBOV-PEP was available although vaccine responses had been shown to occur rapidly in macaques and humans. An interim phase III cluster randomised trial of the replication competent rVSV-ZEBOV vaccine, published in July 2015, indicated 100% efficacy at 10 days post-vaccination and an acceptable side effect profile [3] . In rhesus macaques, it was found to provide protection when given as little as 1 week prior to exposure [4] and had also been used successfully as PEP 49 hours after exposure in a laboratory worker following a high titre needlestick injury [5] . Another6 individuals subsequently received the vaccine following exposure during the 2013-2016 outbreak and none developed EVD [6] .
In view of the evidence of a rapid immune response in vaccinated individuals and the reported safety of the rVSV-ZEBOV vaccine, a decision was made to offer vaccination to those with the highest exposure risk. Vaccinated individuals were subsequently enrolled into the Glasgow Ebola Vaccine 
Methods
Approval process: An international IMT including infection experts from Europe and the USA recommended that vaccination be offered to those with highest exposure risk on the 9 th October 2015, following EVD diagnosis in the index case (Figure 1) . 65 individuals were identified by the Greater Glasgow and Clyde public health team and designated as category 1, 2 or 3 depending on their level of exposure following national guidance ( Supplementary Table 1 ). These cases were rereviewed by 3 infectious diseases physicians, a public health physician and a clinical virologist, incorporating additional expert risk categorisation advice [7] . Those with a recent history of direct exposure to bodily fluids (vomit, diarrhoea, blood, sweat and/or cerebrospinal fluid) were recalled to an emergency vaccination clinic on 10 th -11th October. 26/45 clinic attendees accepted the offer of vaccination with informed consent under local NHS emergency regulations for unlicensed treatments (Figure 2) . The following day, the West of Scotland Research Ethics Committee approved a prospective observational follow-up study (15/WS/0251).
Vaccination:
The vaccine clinic was staffed by 6 doctors, 4 nurses and a receptionist. Any attendee with a temperature of ≥37.5 o C on arrival was immediately screened for EBOV by staff in full PPE (Tyvek suit, rubber boots, overshoes, FFP3 mask, visor, double gloves and apron) (Supplementary 
PCR:
Samples obtained during fever and at days 14 and 28 following vaccination were tested at Edinburgh Royal Infirmary using an adapted version of the Trombley PCR assay [9] . Blood, urine and semen were tested for the presence of the rVSV-ZEBOV vaccine using a VSV RT-PCR [10] . EAV was used as an internal control and had a detection limit of between 50-5pfu/ml. Plasma, urine, sputum, serum, saliva, semen and whole blood were extracted using the NucliSens EasyMAG (bioMérieux, Hampshire, UK) according to manufacturer's instructions. PCR was performed on 6μl of RNA extract with the Platinum RT-PCR mastermix kit (Invitrogen) on an ABI Prism 7500 SDS real-time platform (Applied Biosystems) in a 15μl reaction volume. The following thermal profile was used: 15min at 50 o C and then 95 o C for 15min, followed by 40 cycles of 95 o C for 60s and 60 o C for 60s.
Immunological assays: Antibody assays were carried out at days 14, 28 and 3, 6, 9 and 12 months post-vaccination and T-cell responses measured by IFNγ ELISpot and flow cytometry at 1, 3, 6, 9 and 12 months.
Enzyme linked-immunosorbent assay (ELISA)[11]
High binding microtiter plates were coated with 1µg/ml EBOV GP and incubated for 16-20 hours. Neutralisation assays: Neutralization assays were performed at biosafety level 4 at the Institute of Virology, Philipps-University Marburg, Germany as previously described [12] . Volunteer blood plasma was incubated at 56°C for 30 min for complement inactivation. After centrifugation at 13,000rpm for 10 min, sera were serially diluted from 2 3 -2 10 in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 2% fetal calf serum (FCS, Gibco), penicillin (100U/ml), streptomycin (100mg/ml), and L-glutamine (2mmol/l) (Invitrogen) in 96-well culture plates. 100 TCID50 units of EBOV (Zaire, isolate Mayinga, AF086833) were added to the serum dilutions. Following incubation at 37°C for one hour, Vero cell suspension in DMEM containing 2% FCS was added and incubated at 37°C with 5% CO2. Cytopathic effects (CPE) were evaluated at seven days post infection. Neutralization titers were calculated as GMT of four replicates.
IFNγ-ELISpot assays:
Peripheral blood mononuclear cell (PBMC)s were thawed using warm media and rested overnight at 37°C. The following day they were stimulated with overlapping EBOV glycoprotein peptides (MP1/MP2) as previously described [13] . Plates were counted using an S6 core analyser (Cellular Technology Limited) and results adjusted to spot forming units (SFU)/1x10 6 cells/ml. Analysis required detection of a positive control then subtraction of the non-peptide stimulated control from peptide-stimulated samples.
T-cell phenotyping studies: Intracellular cytokine staining (ISC) was performed as previously described [13] . Briefly, PBMCs were re-suspended in warmed media and rested overnight at 37°C.
The following day, cells were adjusted to 1x10 6 cells/ml in media containing anti-CD28, CD49d and CD107a-PerCP cy5.5 (1 µg/ml). Cells were then untreated or stimulated with EBOV GP peptide pool, containing 187x15mer overlapping peptides at 2.5µg/peptide or 1µg/ml Staphylococcal Enterotoxin 
Statistical analysis
Comparisons were made using parametric or non-parametric methods as appropriate using STATA v10. The sponsor of the study had no role in study design, data collection, analysis or writing of the report.
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Results
Of 65 individuals designated as having had contact with the infected patient, 45 category 3 contacts were found to have had possible direct skin contact with contaminated bodily fluids (vomit, sweat, blood, urine or cerebrospinal fluid (CSF)). None had evidence of percutaneous exposure and all would be categorised as "intermediate" in a more recently proposed exposure risk stratification [7] .
Of these, 26 elected to receive vaccination following written informed consent and agreed to be followed as part of the observational GEVS Study. The median age of those vaccinated was 40 (range 24-67). 15/26 (58%) were healthcare workers and 11/26 (42%) were household contacts. All individuals were followed up within the first 3 months following vaccination but attendance at subsequent follow-up clinics was incomplete due to movement of medical and nursing staff to other cities within the UK (Supplementary Table 2) . No-one exposed to the virus became infected. All samples tested for EBOV and VSV were negative, including two febrile clinic attendees tested for EBOV prior to vaccination. Figure 3 . A positive anti-GP IgM response peaked at 14-28 days post-vaccination (Figure 3b ) and negatively correlated with the emergence of neutralising antibody responses (Supplementary Figure 4) . Neutralising antibody Figure 3c ).
T-cell responses:
IFNγ ELISpot responses to GP were detected at all timepoints, followed a similar pattern to neutralisation over time (Supplementary Figure 5 ) and peaked at 6 months postvaccination (Figure 3d) . Individual responses are shown in Supplementary Figure 6 .
Side effects: Side effects were common but mild in the majority of cases and were characterised by a syndrome of fatigue, myalgia, headache and arthralgia ( Table 1) . The presence of one symptom was strongly associated with the presence of others (Fisher exact test, p<0.0001). During the first 72 hours of follow-up, 50% of individuals developed a fever ≥37.5 o C, requiring in-hospital assessment and testing for EBOV. While the median duration of side effects was 0-1 days, a small number of patients developed long-standing symptoms of fatigue (up to 343 days), arthralgia (up to 261 days) and headache (up to 108 days). Two patients experienced long-lasting symptoms of arthralgia, one of whom had a diagnosis of osteoarthritis and flexor tendonitis thought to be unrelated to vaccination following specialist rheumatological review. Further details on cases of arthralgia are shown in Supplementary Table 3 . Symptoms of arthralgia, myalgia and fatigue occurring at the time of sampling were significantly associated with a higher proportion of CD8+IFNγ and CD4+IL2 secreting cells while headache was associated with higher CD4+IL2 (Figures 4a-d) and IFNγ ELISpot response. No significant association with IgM, IgG or neutralising antibody responses was found ( Supplementary Table 4 ). 
Discussion
The risk of transmission of EBOV to household contacts and healthcare workers exposed to infected bodily fluids is high, particularly prior to diagnosis when the risks may not be fully appreciated.
During the West Africa 2013-16 outbreak, several infected individuals travelled by air to other countries resulting in onward transmission. In Spain, a nurse became infected after caring for a patient transferred for specialist care and in the United States, two nurses became infected after contact with an undiagnosed infected traveller. In Nigeria, 20 people were infected (11 healthcare workers) following a single introduction [14] . No randomised studies on the use of PEP have been carried out in humans but vaccination and antiviral agents have been studied in exposed individuals on a case-by-case basis [6, 7] and more recently in a large outbreak in DRC.
The rVSV-ZEBOV vaccine is a highly effective vaccine that rapidly protects mice, hamsters, guinea pigs, non-human primates and humans from infection with EBOV when administered prior to exposure. In humans, ring vaccination with rVSV-ZEBOV at a dose of 2x10 7 pfu was highly effective at preventing infection in contacts and contacts of contacts of individuals with EBOV infection in West Africa in a large phase III trial [15] . In this study, which initially involved an immediate and a delayed vaccine arm, no infections occurred 10 days after vaccination in any recipient (100% vaccine efficacy). As a result, randomisation was halted by an independent safety board and all subsequent participants in the study were offered immediate vaccination. Vaccination was carried out a median of 7.3 and 9.8 days following index patient symptom onset in the immediate and non-randomised vaccine rings respectively. Importantly, EBOV infection did occur in the 10-day period postvaccination and this was not reduced compared with the delayed vaccination arm. This indicates that the timing of the use of the vaccine is likely to be critical and would need to stimulate a protective immune response early within the median 9-10 day incubation period.
In rhesus macaques (in whom infection is uniformly fatal with a more rapid onset of disease [6] ), a single dose of the vaccine provides complete protection when given as little as 7 days before [4, 16] and prevents infection in 50% when given as PEP 24 hours after infection [17] .
Immunity is likely to be largely innate or antibody-dependent as depletion of CD4 or CD8+ cells postchallenge does not abrogate protection [18] .
The first use of rVSV-ZEBOV in a human was reported in 2011 following a high-titre needlestick exposure in a laboratory [5] . In this case, a single dose of 5x10 7 pfu was administered 48 hours after the accident. At least 6 other individuals have now also received the vaccine, given 1-3 days postexposure, the majority having been exposed in Ebola Treatment Units (ETUs) during the 2014-2016
West Africa outbreak [5, 19, 20] . All of these individuals were given a higher dose of vaccine and all developed significant side effects although none became infected ( Table 2) . In this intervention, the 2x10 7 pfu dose was selected as a balance between very high levels of reactogenicity found with the 1x10 8 pfu dose and the lower immune responses found in individuals treated with lower doses in phase I and II studies [10, 12, 21] . We detected a higher incidence of symptoms in our study compared with these trials [10] but lower than that found in the cases described in Table 2 . The high incidence of symptoms may be related to variation in genetic background and high levels of psychological stress.
The risk of infection was likely to have been highest in those who had contact with body fluids from the index case. While blood and CSF tested positive by PCR, infectious virus was only isolated from the CSF where the titre was highest [22] (vomit, urine, saliva and rectal swabs all subsequently tested PCR-negative). In retrospect, the individuals with the highest potential risk of transmission were those exposed to CSF during the lumbar puncture procedure that took place 3 days before vaccination.
The mechanism of protection following vaccination with rVSV-ZEBOV may involve innate, T-cell mediated and/or B-cell mediated responses [15, 23, 24] . We assessed the immune response by indirect ELISA, neutralisation with live ZEBOV(Mayinga strain), ELISpot and flow cytometry. There are no definite surrogates of immunity but such responses have been associated with protection from infection in macaques and humans. IgM responses peaked at day 14 while IgG seroconversion occurred in 39% at 14 days post-vaccination increasing to 87% by day 28 and 100% of individuals by 3 months. The day 14 anti-GP seroconversion was lower than that found in rhesus macaques [4, 25, 26] and in human participants in pooled North American phase I studies which showed universal seroconversion by day 14 [27] . In the phase II PREVAIL trials, 77-83% of 500 individuals seroconverted within a month of vaccination [8, 28] . We found the number of individuals with positive neutralising antibody responses were similar to those with anti-GP responses evaluated by ELISA. 75% of individuals were anti-GP positive at 1 year after vaccination and 73% had A c c e p t e d M a n u s c r i p t 16 positive neutralisation results. This is in keeping with a long-lasting effect found in other studies [29] .
T cell responses directed against GP were also detected as described previously [24] .
Future use of rVSV-ZEBOV must be balanced against the risk of side effects. It is a live vaccine and fever in vaccinated individuals has been found to be associated with evidence of replicating rVSV-ZEBOV in blood [30] . The side effect profile of these Scottish vaccine recipients was similar to recipients in Switzerland with a higher prevalence of arthralgia than reported in phase I studies in Germany and Kenya. Arthralgia in Swiss participants lasted a median of 8 days (range 3-167 days; IQR:4-87 days) [12] . As in this study, symptoms were generally short-lived but were longer-lasting in 2 patients. Headache, fatigue, myalgia and arthralgia were associated with the magnitude of T-cell response to pooled GP peptides with higher CD4+ production of IL2 and CD8+ production of IFNγ but not with antibody responses.
There were several limitations to this study. Firstly, we cannot comment on efficacy of the vaccine as this was not a randomised controlled intervention following definitive virus exposure. However, we have demonstrated that Ebola vaccine used as PEP was immunogenic and relatively well-tolerated.
Timing of administration is likely to be critical as some individuals did not develop a rapid immune response. While vaccination is a reasonable PEP strategy, other interventions such as the use of antiviral agents or newer vaccines may be warranted. 
